These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11122819)

  • 21. Synopsis of angiogenesis inhibitors in oncology.
    Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
    Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis.
    Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ
    Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer therapy with angiogenesis inhibitors.
    Ghilardi C; Bani MR; Giavazzi R
    Tumori; 2001; 87(6):S14-6. PubMed ID: 11989610
    [No Abstract]   [Full Text] [Related]  

  • 25. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenesis: an organizing principle for drug discovery?
    Folkman J
    Nat Rev Drug Discov; 2007 Apr; 6(4):273-86. PubMed ID: 17396134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical approaches toward tumor angiogenesis: past, present and future.
    Fujita Y; Abe R; Shimizu H
    Curr Pharm Des; 2008; 14(36):3820-34. PubMed ID: 19128235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor inflammatory angiogenesis and its chemoprevention.
    Albini A; Tosetti F; Benelli R; Noonan DM
    Cancer Res; 2005 Dec; 65(23):10637-41. PubMed ID: 16322203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Redundant angiogenic signaling and tumor drug resistance.
    Gacche RN; Assaraf YG
    Drug Resist Updat; 2018 Jan; 36():47-76. PubMed ID: 29499837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
    Zhang C; Tan C; Ding H; Xin T; Jiang Y
    Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current progress in antivascular tumor therapy.
    Ho YJ; Wang TC; Fan CH; Yeh CK
    Drug Discov Today; 2017 Oct; 22(10):1503-1515. PubMed ID: 28625610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer research. Obstacle for promising cancer therapy.
    Marx J
    Science; 2002 Feb; 295(5559):1444. PubMed ID: 11859164
    [No Abstract]   [Full Text] [Related]  

  • 34. [Targeting angiogenesis in oncology].
    Fayette J; Soria JC; Armand JP
    Pathol Biol (Paris); 2006 May; 54(4):199-205. PubMed ID: 16753494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
    Rosen LS
    Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
    Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
    Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.
    Cherrington JM; Strawn LM; Shawver LK
    Adv Cancer Res; 2000; 79():1-38. PubMed ID: 10818676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiogenesis--a new target for future therapy.
    Pandya NM; Dhalla NS; Santani DD
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.